Showing 7261-7270 of 8881 results for "".
- Study: More Than Half of Postmenopausal Women Experience Female Pattern Hair Losshttps://practicaldermatology.com/news/study-more-than-half-of-postmenopausal-women-experience-female-pattern-hair-loss/2461079/More than half of postmenopausal women experience female pattern hair loss, according to a studypublished online in Menopause. In a new cross-sectional study involving 178 women seen at a menopause clinic, researchers aimed to evaluate the prevalence of female pat
- Study: Dermatologists Open to AIhttps://practicaldermatology.com/news/study-dermatologists-open-to-ai/2461075/Artificial intelligence (AI) may play a welcome role in dermatology, according to researchers from the George Washington University (GW) School of Medicine and Health Sciences (SMHS). AI, such as machine-learning, which has been incorporated into photography, dermoscopy, and confocal mi
- Study: Oral Dutasteride Outperforms Other Male Hair Loss Treatmentshttps://practicaldermatology.com/news/study-oral-dutasteride-outperforms-other-male-hair-loss-treatments/2461073/The top-ranking hair loss treatment for men is dutasteride (Avodart) capsules, at a dose of 0.5 milligrams a day, according to a new meta-analysis of 23 studies published online Feb. 2 in
- Solta Medical Files for IPOhttps://practicaldermatology.com/news/solta-medical-files-for-ipo/2461072/Bausch Subsidiary Solta Medical Corporation is getting ready to go public. The Company publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering ("IPO") of Solta's common shares.
- Study: Bile Acids May Improve Skin Inflammation in Psoriasishttps://practicaldermatology.com/news/study-bile-acids-may-improve-skin-inflammation-in-psoriasis/2461067/Taking bile acids may help control inflammation caused by psoriasis, a UC Davis Health study has found. The study, published in the Journal of Investigative Dermatolog
- Biofrontera Updates Patient Recruitment for Ameluz-PDT Trialhttps://practicaldermatology.com/news/biofrontera-updates-patient-recruitment-for-ameluz-pdt-trial/2461066/Fully 70 percent of the planned 186 patients have been enrolled in Biofrontera Inc.'s phase III clinical study for the treatment of superficial basal cell carcinoma (sBCC) with Ameluz photodynamic therapy (Ameluz-PDT) in combination with the BF-RhodoLED lamp in the U.S, the company repor
- Dupixent Update: Medication Shows Promise in Five Inflammatory Diseaseshttps://practicaldermatology.com/news/dupixent-update-medication-shows-promise-in-five-inflammatory-diseases/2461063/Dupixent (dupilumab) performed well across five diseases with underlying type 2 inflammation. The five diseases include eosinophilic esophagitis, chronic spontaneous urticaria, asthma, chronic rhinosinusitis with nasal polyposis, and atopic dermatitis. Additionally, positive result
- FDA Accepts Label Update for Suneva’s Plasma IQhttps://practicaldermatology.com/news/fda-accepts-label-update-for-sunevas-plasma-iq/2461061/Plasma IQ label, including the removal of the product's eye contraindication. The removal of this specific contraindication was due in part to a compilation of literature provided to the FDA showing the safety and efficacy of the ablative device on skin tissue, particular
- Morgan Dermatology to Expand with Financing from TD Bankhttps://practicaldermatology.com/news/morgan-dermatology-to-expand-with-financing-from-td-bank/2461058/Morgan Dermatology is expanding, thanks to a $1.38 million term loan and $5.26 million Commercial Real Estate Mortgage (CREM) from
- Neutrogena Announces New "Heroes of Skin Health Equity" Initiativehttps://practicaldermatology.com/news/neutrogena-announces-new-heroes-of-skin-health-equity-initiative/2461057/Neutrogena is launching its new Heroes of Skin Health Equity initiative, the brand’s latest effort aimed at closing the gap to skin health equity for those with Black and brown skin. The brand will publicly recognize the work of individuals who are striving to make